Holen Sie sich die Stockscreener-App
2.525
2.52%
-0.055
Schlusskurs vom Vortag:
$2.58
Offen:
$2.59
24-Stunden-Volumen:
140.86K
Relative Volume:
0.26
Marktkapitalisierung:
$43.05M
Einnahmen:
$3.86M
Nettoeinkommen (Verlust:
$-14.44M
KGV:
-3.125
EPS:
-0.808
Netto-Cashflow:
$-26.06M
1W Leistung:
-8.55%
1M Leistung:
+7.94%
6M Leistung:
+2.24%
1J Leistung:
-27.52%
1-Tages-Spanne:
$2.51
$2.59
1-Wochen-Bereich:
$2.51
$2.8494
52-Wochen-Spanne:
$2.05
$7.33
Veru Inc Stock (VERU) Company Profile
Firmenname
Veru Inc
Sektor
Branche
Telefon
(312) 595-9123
Adresse
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.525 | 43.99M | 3.86M | -14.44M | -26.06M | -0.808 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2024-03-28 | Eingeleitet | Raymond James | Outperform |
| 2023-06-07 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
| 2021-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2018-07-03 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Veru Inc Aktie (VERU) Neueste Nachrichten
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib ) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial - Investing News Network
Veru (VERU) Unveils Promising Preclinical Data on Sabizabulin Against Daraxonrasib-Resistant Pancreatic Cancer - GuruFocus
Veru Inc. Announces Sabizabulin Overcomes Daraxonrasib Resistance in Preclinical Pancreatic Cancer Studies and Advances Phase 2b Development Plan - Quiver Quantitative
Veru Stock Price Forecast. Should You Buy VERU? - StockInvest.us
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Veru Inc Earnings Call Highlights Obesity Trial Momentum - TipRanks
Veru (VERU) Shares: Advances 2.33% to $2.64 in Latest Trading; Key Range: the $2.51 to $2.77 Range Remains in Focus in the Latest SessionSmart Money Flow Stocks - vinanet.vn
Veru (VERU) Quarterly Figures: EPS Lands Above Forecast in the Latest Session; After Results: Shares Finish 1.93% Higher on the DayDebt Analysis Report - vinanet.vn
Veru (VERU) Quarter in Focus: The Available Earnings Metric Delivers a Beat for the Current Session; Trading Response: The Stock Records a 1.52% Decrease for the Current SessionEarnings Analysis - vinanet.vn
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check: Shares Finish 1.52% Down in the Latest ReadingEarnings Deceleration Risk - dars.gov.et
Veru (VERU) Earnings Data Review: EPS Exceeds Its Estimate in the Latest Reading; Share-Price Check - vinanet.vn
Veru Inc (VERU) (Q3 2026) Earnings Call Highlights: Enobosarm Pr - GuruFocus
Veru (VERU) chief scientist adds 1,800 shares in open-market buy - Stock Titan
Veru (VERU) Q3 2026 Earnings Call Transcript - AOL.com
Veru Inc. (VERU) Q2 2026 Earnings: Narrower Loss of $0.30 Per Share Beats Estimates by 8.09%Cash Flow Report - dars.gov.et
Veru 3Q Loss $6.99M >VERU - Moomoo
Veru Releases Q3 2026 Financial Results - AlphaStreet
Veru Q3 2026 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veru posts Q3 2026 EPS beat as PLATEAU trial advances - Investing.com Nigeria
VERU: PLATEAU trial enrollment completed, interim data due Q1 2027, and patent protection extended to 2044 - TradingView
VERU INC. 3Q 2026: Revenue $0 Net loss $6.99M, EPS ($0.3) — 10-Q Summary - TradingView
VERU: PLATEAU trial fully enrolled; cash supports operations past interim data; key patent secured - TradingView
VERU: Net loss narrowed, cash increased, but going concern risk remains amid clinical trial progress - TradingView
Q3 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026 - marketscreener.com
Veru Reports $7 Million Fiscal Q3 Net Loss as PLATEAU Enrolls 239 - Quiver Quantitative
Veru Reports Q3 FY2026: Net Loss $7.0M, Cash $23.9M; PLATEAU Trial Fully Enrolled - TradingView
Veru completes enrollment of obesity drug trial with 239 patients - Investing.com
Veru Q3 Results: EPS beats estimates, losses narrow 40% YoY - scanx.trade
Veru Inc. Reports Full Enrollment of Phase 2b PLATEAU Trial of Enobosarm and Semaglutide Combination and Reaffirms Q1 2027 Interim Data Timeline - Quiver Quantitative
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - The Manila Times
Veru completes enrollment of obesity drug trial with 239 patients By Investing.com - Investing.com UK
VERU: PLATEAU trial fully enrolled; Q3 net loss narrows and patent protection extended to 2044 - TradingView
Veru Inc (VERU) Stock News Today - TradingKey
VERU Q3 2026 Earnings Preview: Recent $VERU Insider Trading, Hedge Fund Activity, and More - Moomoo
Veru Inc (VERU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veru Inc. expected to post a loss of 32 cents a shareEarnings Preview - TradingView
VERU Q3'26 Earnings: EPS estimate is (0.32) USD - TradingView
Veru receives patent allowance for enobosarm combination therapy - Investing.com
Veru receives patent allowance for enobosarm combination therapy By Investing.com - Investing.com Canada
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss - The Manila Times
VeruInterim Analysis Results Expected Q1 2 - Moomoo
Veru Announces Notice of Allowance for Key Me - Moomoo
Veru receives US patent allowance for enobosarm with semaglutide for quality weight loss until 2044 - Pluang
Veru Inc. Announces August 10, 2026 Conference Call to Discuss Fiscal Third Quarter Results and Business Update - Quiver Quantitative
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th - The Manila Times
Veru to report Q3 fiscal 2026 results on August 10, highlighting obesity drug trial progress. - Pluang
Veru Inc. (VERU) Edges Higher: Stock Climbs 0.90% to $2.24Pairs Trade - dars.gov.et
VERU Q2 2026 Earnings: Loss Narrows Sharply, Beats Estimates by 58.7%Analyst Earnings Estimate - vinanet.vn
Veru Inc (NASDAQ: VERU) Share Price, VERU Stock News, VERU Share Price & Updates - Kalkine
Veru Inc. (VERU) Holds Steady Near Support as Biotech Sector Remains CautiousOBV Divergence - dars.gov.et
Finanzdaten der Veru Inc-Aktie (VERU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):